ArticleInflammopharmacology2026
Gastroprotective potential of fatty compounds from Persea americana seed: an experimental report.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Persea americana (Lauraceae) is a fruit widely cultivated in tropical and subtropical regions, commonly known as the avocado. Although the seeds represent a considerable portion of the whole fruit, scientific research on their phytochemistry and biological effects is still in its early stages. This study investigated the gastroprotective effect of the crude methanolic extract (CME-PA; 30-300 mg/kg), the fractions hexane (HF-PA; 100-1000 mg/kg), dichloromethane (DCMF-PA; 30-1000 mg/kg), and ethyl acetate (EAF-PA; 1000 mg/kg) at doses proportional to their yields, as well as isolated compounds (1-4) and a mixture of compounds (M). Gastroprotection was evaluated using the acidified ethanol-induced ulcer model. In addition, the study assessed histological, oxidative, and inflammatory parameters in the gastric mucosa, as well as the in vitro anti-H. pylori activity. Although CME-PA did not prevent the onset of gastric lesions, the HF-PA (300 and 1000 mg/kg), DCMF-PA (1000 mg/kg), and EAF-PA (1000 mg/kg) fractions attenuated acidified ethanol-induced injury by 56.73%, 74.93%, 80.53%, and 52.91%, respectively. Similarly, compounds 4 (300 mg/kg) and M (1, 3, and 10 mg/kg) reduced lesion formation by 52.16%, 56.02%, 66.90%, and 72.89%. Furthermore, compounds 4 (300 mg/kg) and M (3 mg/kg) increased PAS-stained mucin content. Notably, the mixture M, at all tested doses, enhanced the antioxidant defenses of the gastric mucosa and reduced inflammation. Despite these findings, the extract, fractions, and isolated compounds did not exhibit anti-H. pylori activity. Overall, this study provides promising phytochemical and pharmacological evidence, given the significant gastroprotective effects of fractions and isolated compounds against acidified ethanol-induced gastric ulcers. These results highlight the potential of P. americana seeds, often regarded as a by-product of the fruit, as a valuable natural resource for the prevention of gastric ulcer disease.
Indexed as
Identifiers
42850415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.